Not provided
Not provided
Not provided
Not provided
Not provided
Decision Sponsor
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cantonal Hospital of St. Gallen | OTHER |
Not provided
Not provided
Not provided
Not provided
This clinical trial investigates the safety and the preliminary clinical benefit of the hemiverse shoulder prosthesis. Implantation of this newly developed hemi-prosthesis is intended for patients who do not qualify for a regular reverse or hemi-prosthesis due to severe medical conditions, poor bone stock or critical status of the rotator cuff. The expected benefit is, that patients will have a minimally invasive surgical procedure, only addressing the humeral shaft, however with the biomechanical advantage of a total reverse shoulder prosthesis, meaning, that with a minimally invasive surgery a comparable result as with a regular total shoulder prosthesis is accomplished. Patients will be closely monitored within the study protocol for 24 months and thereafter in regular interval as with a normal prosthetic follow-up.
This clinical trial investigates the safety and the preliminary clinical benefit of the hemiverse shoulder prosthesis. Implantation of this newly developed hemi-prosthesis is intended for patients who do not qualify for a regular reverse or hemi-prosthesis due to severe medical conditions, poor bone stock or critical status of the rotator cuff.
To evaluate the clinical condition of the patient a clinical examination including evaluation of the
Surgical procedure:
A delto-pectoral approach is preferred. The incision starts immediately lateral to the coracoid tip and extends to the insertion of the deltoid on the Humerus. The subscapularis tendon is exposed and detached from the humerus. The humeral head is exposed and dislocated from the joint using an oscillating saw the humeral head is resected. The shaft is prepared to receive a regular humeral stem which is definitely implanted with 0° retroversion. A trial implant is inserted and reduced into the joint. Free mobility of the joint is tested and the stability of the implant documented. According to the trial implants the definite implant is assembled and implanted. After reduction of the implant the subscapularis tendon is reattached to the humerus using transosseous sutures. Regular closure of the incision is performed.
After-care:
Immediately post operatively a anteroposterior radiograph is performed. For the first two post-operative weeks the arm is immobilised in a sling and external rotation is allowed until 0° and flexion until 90° in internal rotation. Thereafter gradual increase of active mobility is allowed until the weeks post operatively, when full load bearing of the arm is allowed. Regular follow-up visits include evaluation of the Constant-Murley score, Subject shoulder value and visual analogue scale. Additionally conventional radiographic status (anteroposterior lateral and axillary view) are performed post-operatively on day 1 or 2, week 6, 4.5 months, 6 months, 1 year and 2 years.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention/treatment | Experimental | Implantation of the Hemiverse Shoulder Prothesis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Device: Hemiverse | Other | Implantation of the hemiverse shoulder prothesis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at day 1 or 2 |
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at day 7 |
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at week 6 |
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at month 4.5 |
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at month 6 |
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at month 12 |
| Adverse Event: Occurence of a fracture | Fracture of the humerus, the scapula and/or the clavicle (yes/no). | Assessments will take place after implantation at month 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Change of pain using a visual analogue scale: 0-100, 0=no pain 100=maximal imaginable pain | Highest pain level within last 25 hours will be recorded on a visual analogue scale | Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24 |
| Change of active range of motion |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bernhard Jost, MD | Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kantonsspital St. Gallen, Klinik für Orthopädische Chirurgie und Traumatologie des Bewegungsapparates | Sankt Gallen | Canton of St. Gallen | 9007 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000070636 | Rotator Cuff Injuries |
| D012421 | Rupture |
| D014947 | Wounds and Injuries |
| D000070599 | Shoulder Injuries |
| D013708 | Tendon Injuries |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at day 1 or 2 |
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at day 7 |
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at week 6 |
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at month 4.5 |
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at month 6 |
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at month 12 |
| Adverse Event: Occurence of an infection | Infection at the implantation site (yes/no). | Assessments will take place after implantation at month 24 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at day 1 or 2 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at day 7 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at week 6 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at month 4.5 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at month 6 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at month 12 |
| Adverse Event: Occurence of a hematoma | Presence of a hematoma at the implantation site (yes/no). | Assessments will take place after implantation at month 24 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at day 1 or 2 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at day 7 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at week 6 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at month 4.5 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at month 6 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at month 12 |
| Adverse Event: Occurence of nerve damage | Nerve damage (yes/no). | Assessments will take place after implantation at month 24 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at day 1 or 2 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at day 7 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at week 6 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at month 4.5 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at month 6 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at month 12 |
| Adverse Event: Occurence of implant dislocation | Dislocation of the implant (yes/no). | Assessments will take place after implantation at month 24 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at day 1 or 2 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at day 7 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at week 6 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at month 4.5 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at month 6 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at month 12 |
| Adverse Event: Occurence of pulmonary embolism | Pulmonary embolism (yes/no). | Assessments will take place after implantation at month 24 |
Active range of motion of the patient will be measured using a handheld goniometer for active elevation, abduction, external rotation and internal rotation |
| Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24 |
| Change of strength of abduction | isometric strength of abduction will be measured at 90 degrees scapular abduction using a validated device | Assessment will take place at screening and the day before implantation and week 6, month 4.5, month 6, month 12 and month 24 |